The American Cancer Society 2035 challenge goal on cancer mortality reduction.
Adult
Age Distribution
Aged
American Cancer Society
Antineoplastic Agents, Hormonal
/ therapeutic use
Early Detection of Cancer
/ standards
Female
Goals
Humans
Male
Mass Screening
/ standards
Middle Aged
Models, Statistical
Mortality
/ trends
Neoplasms
/ diagnosis
Practice Guidelines as Topic
Risk Factors
Risk Reduction Behavior
Sex Factors
United States
/ epidemiology
breast cancer
cancer
colorectal cancer
lung cancer
mortality
prostate cancer
risk factor
Journal
CA: a cancer journal for clinicians
ISSN: 1542-4863
Titre abrégé: CA Cancer J Clin
Pays: United States
ID NLM: 0370647
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
pubmed:
9
5
2019
medline:
11
4
2020
entrez:
9
5
2019
Statut:
ppublish
Résumé
A summary evaluation of the 2015 American Cancer Society (ACS) challenge goal showed that overall US mortality from all cancers combined declined 26% over the period from 1990 to 2015. Recent research suggests that US cancer mortality can still be lowered considerably by applying known interventions broadly and equitably. The ACS Board of Directors, therefore, commissioned ACS researchers to determine challenge goals for reductions in cancer mortality by 2035. A statistical model was used to estimate the average annual percent decline in overall cancer death rates among the US general population and among college-educated Americans during the most recent period. Then, the average annual percent decline in the overall cancer death rates of college graduates was applied to the death rates in the general population to project future rates in the United States beginning in 2020. If overall cancer death rates from 2020 through 2035 nationally decline at the pace of those of college graduates, then death rates in 2035 in the United States will drop by 38.3% from the 2015 level and by 54.4% from the 1990 level. On the basis of these results, the ACS 2035 challenge goal was set as a 40% reduction from the 2015 level. Achieving this goal could lead to approximately 1.3 million fewer cancer deaths than would have occurred from 2020 through 2035 and 122,500 fewer cancer deaths in 2035 alone. The results also show that reducing the prevalence of risk factors and achieving optimal adherence to evidence-based screening guidelines by 2025 could lead to a 33.5% reduction in the overall cancer death rate by 2035, attaining 85% of the challenge goal.
Substances chimiques
Antineoplastic Agents, Hormonal
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
351-362Informations de copyright
© 2019 American Cancer Society.
Références
Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981;66:1191-1308.
Bailar JC 3rd, Smith EM. Progress against cancer? N Engl J Med. 1986;314:1226-1232.
Byers T, Wender RC, Jemal A, Baskies AM, Ward EE, Brawley OW. The American Cancer Society challenge goal to reduce US cancer mortality by 50% between 1990 and 2015: results and reflections. CA Cancer J Clin. 2016;66:359-369.
Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008;100:1672-1694.
Jemal A, Ward E, Thun M. Declining death rates reflect progress against cancer. PLoS One. 2010;5:e9584.
Cronin KA, Lake AJ, Scott S, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer. 2018;124:2785-2800.
Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97:1407-1427.
Siegel RL, Jemal A, Wender RC, Gansler T, Ma J, Brawley OW. An assessment of progress in cancer control. CA Cancer J Clin. 2018;68:329-339.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34.
Lortet-Tieulent J, Soerjomataram I, Lin CC, Coebergh JWW, Jemal A. U.S. burden of cancer by race and ethnicity according to disability-adjusted life years. Am J Prev Med. 2016;51:673-681.
Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212-236.
Jemal A, Robbins AS, Lin CC, et al. Factors that contributed to black-white disparities in survival among nonelderly women with breast cancer between 2004 and 2013. J Clin Oncol. 2018;36:14-24.
Robbins AS, Siegel RL, Jemal A. Racial disparities in stage-specific colorectal cancer mortality rates from 1985 to 2008. J Clin Oncol. 2012;30:401-405.
Naishadham D, Lansdorp-Vogelaar I, Siegel R, Cokkinides V, Jemal A. State disparities in colorectal cancer mortality patterns in the United States. Cancer Epidemiol Biomarkers Prev. 2011;20:1296-1302.
Ross K, Kramer MR, Jemal A. Geographic inequalities in progress against lung cancer among women in the United States, 1990-2015. Cancer Epidemiol Biomarkers Prev. 2018;27:1261-1264.
Siegel RL, Sahar L, Portier KM, Ward EM, Jemal A. Cancer death rates in US congressional districts. CA Cancer J Clin. 2015;65:339-344.
Jemal A, Siegel RL, Ma J, et al. Inequalities in premature death from colorectal cancer by state. J Clin Oncol. 2015;33:829-835.
Jemal A, Simard EP, Xu J, Ma J, Anderson RN. Selected cancers with increasing mortality rates by educational attainment in 26 states in the United States, 1993-2007. Cancer Causes Control. 2013;24:559-565.
Kinsey T, Jemal A, Liff J, Ward E, Thun M. Secular trends in mortality from common cancers in the United States by educational attainment, 1993-2001. J Natl Cancer Inst. 2008;100:1003-1012.
Ma J, Siegel RL, Islami F, Jemal A. Temporal trends in liver cancer mortality by educational attainment in the United States, 2000-2015 [published online April 8, 2019]. Cancer. doi:10.1002/cncr.32023
Islami F, Goding Sauer A, Miller KD, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018;68:31-54.
Goding Sauer A, Siegel RL, Jemal A, Fedewa SA. Current prevalence of major cancer risk factors and screening test use in the United States: disparities by education and race/ethnicity. Cancer Epidemiol Biomarkers Prev. 2019;28:629-642.
Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94:334-357.
Gapstur SM, Drope JM, Jacobs EJ, et al. A blueprint for the primary prevention of cancer: targeting established, modifiable risk factors. CA Cancer J Clin. 2018;68:446-470.
Wender RC, Brawley OW, Fedewa SA, Gansler T, Smith RA. A blueprint for cancer screening and early detection: advancing screening's contribution to cancer control. CA Cancer J Clin. 2019;69:50-79.
Yabroff KR, Gansler T, Wender RC, Cullen KJ, Brawley OW. Minimizing the burden of cancer in the United States: goals for a high-performing health care system [published online February 20, 2019]. CA Cancer J Clin. 2019;69:166-183.
Alfano CM, Leach CR, Smith TG, et al. Equitably improving outcomes for cancer survivors and supporting caregivers: a blueprint for care delivery, research, education, and policy. CA Cancer J Clin. 2019;69:35-49.
Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Mortality-All COD, Aggregated With State, Total US (1969-2015) <Katrina/Rita Population Adjustment> (underlying mortality data provided by National Center for Health Statistics). Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2017.
Centers for Disease Control and Prevention, National Center for Health Statistics. National Vital Statistics System: Datasets and Related Documentation for Mortality Data. cdc.gov/nchs/nvss/mortality_methods.htm. Accessed December, 10, 2018.
The United States Census Bureau. American Community Survey (ACS). PUMS Data. census.gov/programs-surveys/acs/data/pums.html. Accessed December, 10, 2018.
National Center for Health Statistics. National Health Interview Survey. cdc.gov/nchs/nhis/data_questionnaires.htm. Accessed December, 10, 2018.
Haughwout SP, Slater ME. Apparent per capita alcohol consumption: national, state, and regional trends, 1977-2016. Surveillance Report 110. Arlington, VA: CSR Incorporated for the National Institute on Alcohol Abuse and Alcoholism; 2018.
Rey G, Boniol M, Jougla E. Estimating the number of alcohol-attributable deaths: methodological issues and illustration with French data for 2006. Addiction. 2010;105:1018-1029.
National Center for Health Statistics. National Health and Nutrition Examination Survey. cdc.gov/nchs/nhanes/Default.aspx. Accessed December 10, 2018.
Crew KD, Albain KS, Hershman DL, Unger JM, Lo SS. How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? NPJ Breast Cancer. 2017;3:20.
Waters EA, Cronin KA, Graubard BI, Han PK, Freedman AN. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev. 2010;19:443-446.
Ma J, Xu J, Anderson RN, Jemal A. Widening educational disparities in premature death rates in twenty six states in the United States, 1993-2007. PLoS One. 2012;7:e41560.
Singh GK, Jemal A. Socioeconomic and racial/ethnic disparities in cancer mortality, incidence, and survival in the United States, 1950-2014: over six decades of changing patterns and widening inequalities. J Environ Public Health. 2017;2017:2819372.
Albano JD, Ward E, Jemal A, et al. Cancer mortality in the United States by education level and race. J Natl Cancer Inst. 2007;99:1384-1394.
Wang TW, Asman K, Gentzke AS, et al. Tobacco product use among adults-United States, 2017. MMWR Morb Mortal Wkly Rep. 2018;67:1225-1232.
Ogden CLFT, Carroll MD, et al. Prevalence of obesity among adults, by household income and education-United States, 2011-2014. MMWR Morb Mortal Wkly Rep. 2017;66:1369-1373.
Siegel RL, Fedewa SA, Anderson WF, et al. Colorectal cancer incidence patterns in the United States, 1974-2013. J Natl Cancer Inst. 2017;109:djw322.
Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177-193.
Sung H, Siegel RL, Rosenberg PS, Jemal A. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health. 2019;4:e137-e147.
Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784-1792.
Etzioni R, Gulati R, Tsodikov A, et al. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer. 2012;118:5955-5963.
Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079-1092.
Rohrmann S, Genkinger JM, Burke A, et al. Smoking and risk of fatal prostate cancer in a prospective U.S. study. Urology. 2007;69:721-725.
Islami F, Moreira DM, Boffetta P, Freedland SJ. A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur Urol. 2014;66:1054-1064.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7-30.
Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605-1617.
Welzel TM, Graubard BI, Quraishi S, et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol. 2013;108:1314-1321.
Vutien P, Jin M, Le MH, et al. Regional differences in treatment rates for patients with chronic hepatitis C infection: systematic review and meta-analysis. PLoS One. 2017;12:e0183851.
Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31:1090-1101.
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625-1638.
Al-Qurayshi Z, Crowther JE, Hamner JB, Ducoin C, Killackey MT, Kandil E. Disparities of immunotherapy utilization in patients with stage III cutaneous melanoma: a national perspective. Anticancer Res. 2018;38:2897-2901.
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1714-1768.
US Preventive Services Task Force, Curry SJ, Krist AH, et al. Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: US Preventive Services Task Force recommendation statement. JAMA. 2018;320:1163-1171.
Klabunde CN, Schenck AP, Davis WW. Barriers to colorectal cancer screening among Medicare consumers. Am J Prev Med. 2006;30:313-319.
Park ER, Gareen IF, Japuntich S, et al. Primary care provider-delivered smoking cessation interventions and smoking cessation among participants in the National Lung Screening Trial. JAMA Intern Med. 2015;175:1509-1516.
Vespa J, Armstrong DM, Medina L. Demographic Turning Points for the United States: Population Projections for 2020 to 2060. Report P25-1144. census.gov/content/dam/Census/library/publications/2018/demo/P25_1144.pdf. Accessed November 1, 2018.
Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003;95:526-532.
Fedewa SA, Flanders WD, Ward KC, et al. Racial and ethnic disparities in interval colorectal cancer incidence: a population-based cohort study. Ann Intern Med. 2017;166:857-866.
Forrest LF, Adams J, Rubin G, White M. The role of receipt and timeliness of treatment in socioeconomic inequalities in lung cancer survival: population-based, data-linkage study. Thorax. 2015;70:138-145.
Jayadevappa R, Chhatre S, Johnson JC, Malkowicz SB. Variation in quality of care among older men with localized prostate cancer. Cancer. 2011;117:2520-2529.
LeMasters T, Madhavan SS, Sambamoorthi U, Hazard-Jenkins HW, Kelly KM, Long D. Receipt of guideline-concordant care among older women with stage I-III breast cancer: a population-based study. J Natl Compr Canc Netw. 2018;16:703-710.
Lin CC, Bruinooge SS, Kirkwood MK, et al. Association between geographic access to cancer care and receipt of radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2016;94:719-728.
Rhoads KF, Cullen J, Ngo JV, Wren SM. Racial and ethnic differences in lymph node examination after colon cancer resection do not completely explain disparities in mortality. Cancer. 2012;118:469-477.